A Phase 1 interventional study of Sitagliptin phosphate anhydrous formulation and Comparator: sitagliptin phosphate monohydrate form in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-08-19.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus, Type 2 · Merck & Co., Inc.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 162nd largest by enrollment of the 170 interventional ones that give a count, is one of 9 that started in 2004, is one of 55 in phase 1, and was the 83rd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
181 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 9 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 192 across the 170 interventional studies, 1,069 across the 11 observational. Of the 181 that completed or were terminated, 150 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will establish that the MK0431 100 mg anhydrous formulation tablets are bioequivalent to the MK0431 100 mg monohydrate final market image (FMI) tablets.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sitagliptin anhydrous formulation
Drug: Sitagliptin phosphate anhydrous formulation
Sitagliptin monohydrate FMI formulation
Drug: Comparator: sitagliptin phosphate monohydrate form
Single dose sitagliptin 100 mg tablets (anhydrous form) in one of two treatment periods.
Single dose sitagliptin 100 mg tablets \[monohydrate Final Market Image (FMI) form\] in one of two treatment periods.
Area Under the Curve (AUC(0 to Infinity)) Following Single Dose Administration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)
Area Under the Plasma Concentration-Time Curve and peak concentration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)
Time frame: Through 72 Hours Following the Administration of the Medication
Peak Plasma Concentration (Cmax) Following Single Dose Administration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)
Peak Plasma concentration (Cmax) for the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)
Time frame: Through 72 Hours Following the Administration of the Medication
| Milestone | 100 mg MK0431 Anhydrous Then 100 mg MK0431 Monohydrate | 100 mg MK0431 Monohydrate Then 100 mg MK0431 Anhydrous |
|---|---|---|
| Started | 6 | 6 |
| Completed | 6 | 6 |
| Not completed | 0 | 0 |
| Milestone | 100 mg MK0431 Anhydrous Then 100 mg MK0431 Monohydrate | 100 mg MK0431 Monohydrate Then 100 mg MK0431 Anhydrous |
|---|---|---|
| Started | 6 | 6 |
| Completed | 6 | 6 |
| Not completed | 0 | 0 |
Area Under the Plasma Concentration-Time Curve and peak concentration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)
| μmol*hr/L | 100 mg MK0431 Anhydrous | 100 mg MK0431 Monohydrate |
|---|---|---|
| Area Under the Curve (AUC(0 to Infinity)) Following Single Dose Administration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin) | 8.38 ± 0.77 | 8.78 ± 0.86 |
Peak Plasma concentration (Cmax) for the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)
| μmol/L | 100 mg MK0431 Anhydrous | 100 mg MK0431 Monohydrate |
|---|---|---|
| Peak Plasma Concentration (Cmax) Following Single Dose Administration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin) | 799 ± 164 | 856 ± 180 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 100 mg MK0431 Anhydrous Then 100 mg MK0431 Monohydrate | — | 0/12 (0%) | 3/12 (25%) |
| 100 mg MK0431 Monohydrate Then 100 mg MK0431 Anhydrous | — | 0/12 (0%) | 5/12 (41.7%) |
| Event | 100 mg MK0431 Anhydrous Then 100 mg MK0431 Monohydrate | 100 mg MK0431 Monohydrate Then 100 mg MK0431 Anhydrous |
|---|---|---|
| HeadacheNervous system disorders | 3/12 | 2/12 |
| NauseaGastrointestinal disorders | 1/12 | 1/12 |
| VomitingGastrointestinal disorders | 0/12 | 1/12 |
| AstheniaGeneral disorders | 0/12 | 1/12 |
| Upper Respiratory Tract InfectionInfections and infestations | 0/12 | 1/12 |
| Thermal BurnInjury, poisoning and procedural complications | 0/12 | 1/12 |
| Musculoskeletal StiffnessMusculoskeletal and connective tissue disorders | 0/12 | 1/12 |
| DizzinessNervous system disorders | 0/12 | 1/12 |
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 45.3 (41 to 54) |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 6 |
| Male | 6 |
| Height(Centimeters) | All Participants |
|---|---|
| Mean | 170.5 (156.5 to 179.0) |
| Weight(Kilograms) | All Participants |
|---|---|
| Mean | 75.3 (56.6 to 88.3) |
No study locations are listed for this record.
The record gives a start of Aug 2004, a primary completion of Sep 2004 and a completion of Nov 2004. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2010, 5 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.